Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadoversetamide
Drug ID BADD_D00994
Description Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.
Indications and Usage Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.
Marketing Status approved; investigational
ATC Code V08CA06
DrugBank ID DB00538
KEGG ID D01646
MeSH ID C112666
PubChem ID 444013
TTD Drug ID D0X0GI
NDC Product Code Not Available
UNII RLM74T3Z9D
Synonyms gadoversetamide | OptiMARK
Chemical Information
Molecular Formula C20H34GdN5O10
CAS Registry Number 131069-91-5
SMILES COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eructation07.01.02.003--
Erythema multiforme23.03.01.003; 10.01.03.015--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Flatulence07.01.04.002--
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hypercalcaemia05.04.01.002; 14.04.01.003--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia15.05.04.007; 17.05.02.001--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Influenza like illness08.01.03.010--
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site oedema12.07.03.024; 08.02.03.024--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Laryngospasm22.04.02.002--
Malaise08.01.01.003--
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages